MedTrace Logo

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-10-19

Study results available
· View outcomes & findings →

Summary

The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.

Conditions

  • Fuchs Endothelial Dystrophy

Interventions

DRUG

Netarsudil Ophthalmic Solution

Netarsudil eye drops instilled once daily

DRUG

Placebo

Placebo eye drops instilled once daily

Sponsors & Collaborators

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, Jr, MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-05
Primary Completion
2020-07-01
Completion
2020-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04051463 on ClinicalTrials.gov